Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions

Alzheimer Disease

Interventions

DRUG

GSI-953

OTHER

Placebo

Trial Locations (1)

Glendale

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00479219 - Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients | Biotech Hunter | Biotech Hunter